Developer docs
API playgroundTry for free, no card

Search company profiles

Arrakis Therapeutics

Full company profile

uuid0000gdu

Namestring
Arrakis Therapeutics
Legal namestring
Arrakis Therapeutics
Websiteurl
arrakistx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Arrakis Therapeutics is a private biopharmaceutical company founded in 2015 and headquartered in Waltham, Massachusetts, that pioneers the discovery of RNA-targeted small molecule (rSM) medicines — a new therapeutic class designed to directly bind and modulate disease-causing RNA structures with orally bioavailable small molecules. The company has built a proprietary end-to-end discovery platform integrating RNA bioinformatics (TRYST), photoaffinity-based binding site mapping (PEARL-seq), open-source structure analysis tools (SHAPEware), curated chemical libraries, RNA-specific assays, and AI/ML-driven chemotype analysis. Its lead wholly-owned candidate is an oral rSM for myotonic dystrophy type 1 (DM1), with IND filing planned for 2026 supported by preclinical data demonstrating splicing correction and myotonia reversal in vivo with broad biodistribution to skeletal muscle and heart.

The company operates a hybrid business model in which it generates revenue through strategic partnerships and licensing agreements with major pharmaceutical companies — notably a $190M upfront, multi-billion-dollar-potential collaboration with Roche (April 2020) and a $75M upfront, several-billion-dollar-potential collaboration with Amgen for RNA degrader therapeutics (January 2022) — while independently advancing its own pipeline in DM1, oncology, and genetically validated disease targets. Arrakis's customers are enterprise pharmaceutical partners rather than end patients or prescribers; Arrakis leads discovery to a defined point, then partners assume preclinical and clinical development. The company has raised approximately $113M in equity (Series A 2017, Series B 2019) and has not yet commercialized any product.

The company is led by CEO Michael Gilman (former founding CEO of Padlock Therapeutics and Stromedix; executive roles at Biogen and ARIAD), with Founder and Chief Innovation Officer Jennifer Petter (ex-Avila, Celgene, Mersana) and Board Chair Katrine Bosley (former CEO of Editas Medicine and Avila Therapeutics). Its Scientific Advisory Board is chaired by Melissa J. Moore, PhD, Chief Scientific Officer of Moderna's mRNA research platform and a National Academy of Sciences member. Headcount is 51-100, consistent with a mid-stage platform biotech scaling toward clinical development.

Short descriptiontext

Arrakis Therapeutics is a private biopharmaceutical company developing orally bioavailable small molecules that directly bind disease-causing RNA, using a proprietary rSM drug discovery platform. It serves enterprise pharmaceutical partners (Roche, Amgen) via licensing collaborations and advances a wholly-owned DM1 candidate toward IND filing in 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA-targeted drug discovery, small molecule therapeutics, biopharmaceutical platform, neuromuscular disease drugs, RNA bioinformatics
Industry2 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA-targeted small molecule drug discovery
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Collaboration Revenue
TypeLicensing Royalties
Description

Arrakis generates revenue through strategic partnerships with pharmaceutical companies. The company receives upfront payments, preclinical, clinical, and commercial milestone payments, and royalties on products developed through partnerships. Notable deals include Roche ($190M upfront, multi-billion dollar potential) and Amgen ($75M upfront, potential royalties up to low double digits per program)

arrakistx.com
2Series Financing
TypeSubscription Recurring
Description

Pre-revenue biotech company funded through venture capital. Raised $38M Series A (2017) and $75M Series B (2019) from life sciences investors to advance platform development and pipeline programs

arrakistx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arrakis Therapeutics develops RNA-targeted small molecule (rSM) drug candidates through a proprietary end-to-end discovery platform that integrates RNA bioinformatics, chemical biology, RNA-specific assays, and RNA-directed medicinal chemistry. Its lead internal asset is an orally bioavailable rSM drug candidate for myotonic dystrophy type 1 (DM1), with additional programs in oncology and genetically validated targets, and it monetizes the platform through major pharmaceutical collaborations with Roche and Amgen.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Oral administration achieved broad biodistribution including to skeletal muscle and heart in preclinical studies
+3 more records
Product overview1 text field

Arrakis Therapeutics is a biopharmaceutical company pioneering RNA-targeted small molecule (rSM) medicines — a new class of genetic medicines that directly target RNA with small molecules for oral delivery. The company's offering centers on its proprietary rSM Platform, which integrates bioinformatics tools (TRYST), chemical biology techniques (PEARL-seq), and RNA-guided medicinal chemistry to systematically discover and design RNA-targeted small molecules. The rSM Toolkit provides industrial-scale discovery capabilities including SHAPEware (open-source bioinformatics software) for RNA structure analysis. The company's lead product is an oral rSM drug candidate for Myotonic Dystrophy Type 1 (DM1), with additional programs in oncology and genetically validated targets. The platform enables targeting of previously 'undruggable' disease drivers by binding directly to pathogenic RNA sequences.

Product and service3 records
1DM1 Drug Candidate (oral RNA-targeted small molecule for myotonic dystrophy type 1)
CategoryTherapeutic drug candidate
Description

Lead first-in-class, orally administered RNA-targeted small molecule in development for myotonic dystrophy type 1 (DM1). The candidate selectively binds the pathogenic CUG repeat RNA, disrupts toxic nuclear aggregates, releases sequestered MBNL1 splicing factor, and corrects splicing defects that drive myotonia. Indication: patients with myotonic dystrophy type 1 (DM1), a genetic neuromuscular disease affecting skeletal muscle, heart, central nervous system, and gastrointestinal tract.

2rSM Drug Discovery Platform
CategoryDrug discovery platform / partnership offering
Description

Proprietary end-to-end drug discovery platform integrating RNA bioinformatics, structural tools, curated RNA-focused chemical libraries, RNA-specific assays, and RNA-directed medicinal chemistry to systematically discover and design RNA-targeted small molecules. Sold/offered to large pharmaceutical partners through strategic collaboration and licensing agreements; also used for internal pipeline development.

3SHAPEware open-source bioinformatics software
CategoryBioinformatics software
Description

Standalone open-source bioinformatics software tool for analyzing SHAPE-based experimental data to explore and predict RNA secondary structure and potential ligand binding sites. Made freely available to academic and industry RNA researchers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-11
Description

Multi-target collaboration focused on discovery and development of RNA degrader therapeutics creating targeted RNA degraders that selectively destroy RNAs encoding disease-causing proteins by inducing their proximity to nucleases. Arrakis receives $75M upfront for five initial programs with option to nominate additional programs. Eligible for preclinical, clinical, regulatory and sales milestones, and royalties up to low double digits per program. Potential for several billion dollars if all milestones met and program options exercised.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-04-08
Description

Strategic collaboration and license agreement for discovery of RNA-targeted small molecule drugs against broad set of targets across Roche's R&D areas. Arrakis leads discovery and research activities to a defined point, then Roche pursues preclinical and clinical development. Arrakis received $190M upfront payment with potential for multi-billion dollar future payments including preclinical, clinical, commercial and sales milestones and royalties.

3Katrine Bosley (Board Member)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-21
Description

Appointed as Chairman of the Board of Directors. Katrine Bosley is a proven biotech entrepreneur with nearly 30 years experience, former CEO of Editas Medicine and Avila Therapeutics. Brings expertise growing biotech platform companies.

arrakistx.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Ionis is the established leader in antisense oligonucleotide (ASO) therapeutics with multiple approved drugs (Spinraza, Tegsedi, Waylivra, Wainua) and a broad pipeline across neurological, cardiovascular, and rare diseases. As the incumbent in RNA-targeted therapeutics, Ionis is broadly comparable to Arrakis in disease focus (neurology, rare diseases) and represents the alternative modality (ASOs vs. rSMs) for many of the same targets Arrakis is pursuing.

TypeEmerging player
Description

Wave Life Sciences is developing stereopure oligonucleotide therapeutics (PRISM platform) for genetic diseases including DM1, Huntington's disease, and ALS. Comparable to Arrakis in target overlap (DM1, repeat expansion disorders, CNS diseases) and as a competitor pursuing RNA-modulating therapies for the same indications, though via oligonucleotide chemistry rather than small molecules.

TypeDirect peer
Description

Skyhawk Therapeutics develops small molecules that modify RNA splicing using a proprietary platform (SkySTAR) — directly comparable to Arrakis's rSM platform in both modality (RNA-targeting small molecules) and therapeutic focus on neurological and rare diseases. Skyhawk has secured major partnerships with Biogen, Vertex, and Merck, mirroring Arrakis's partnership-driven business model.

4Expansion Therapeutics
TypeDirect peer
Description

Expansion Therapeutics is a repeat-expansion-focused company developing small molecules for diseases caused by trinucleotide and other repeat expansions, including myotonic dystrophy type 1 (DM1) — directly competing with Arrakis's lead DM1 program. Expansion's lead program EX-5050 for DM1 makes it the most direct indication-level competitor to Arrakis.

TypeDirect peer
Description

Remix Therapeutics is developing small molecule therapeutics that modulate RNA processing, with a platform (REMaster) targeting RNA processing machinery to address disease-driving transcripts. Directly comparable to Arrakis in approach (RNA-targeted small molecules) and focus on previously undruggable disease targets across oncology and neurological disease.

TypeDirect peer
Description

Ribometrix is a privately held biotech developing small molecule drugs that target RNA structures, with a proprietary platform combining structural biology, chemistry, and computational methods to identify and optimize RNA-binding small molecules. Directly comparable to Arrakis in technology approach (RNA-targeted small molecules) and platform-driven discovery model.

TypeDirect peer
Description

Dyne Therapeutics is developing oligonucleotide-based therapies for muscle diseases including DM1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy, with a proprietary platform for muscle-targeted delivery. Directly comparable to Arrakis in DM1 focus and in targeting muscle diseases via RNA-modulating approaches, though using a different modality (antisense oligonucleotides).

TypeDirect peer
Description

PTC Therapeutics is advancing RGLS8429, an oligonucleotide-based therapy for DM1, into clinical development — making it a direct indication-level competitor to Arrakis's lead DM1 program. As an established commercial-stage rare disease biotech, PTC represents the most credible near-term competitive threat in the DM1 indication Arrakis is targeting with its lead rSM.

TypeBroad incumbent
Description

Alnylam is the commercial leader in RNA interference (siRNA) therapeutics with multiple approved drugs (Onpattro, Givlaari, Oxlumo, Amvuttra) and a deep pipeline in rare genetic and cardiometabolic diseases. Broadly comparable to Arrakis in therapeutic focus on genetic and rare diseases and as the dominant incumbent in the RNA-targeting therapeutic space, though using a fundamentally different modality (siRNA vs. rSMs).

TypeEmerging player
Description

PepGen is developing conjugated peptide-enhanced oligonucleotide therapeutics for DM1 and Duchenne muscular dystrophy, with a proprietary delivery platform (Enhanced Delivery Oligonucleotide). Directly comparable to Arrakis in DM1 focus and in pursuing RNA-targeting therapeutics for neuromuscular diseases, though using a distinct modality (conjugated oligonucleotides vs. rSMs).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arrakis Therapeutics

RNA-targeted small molecule drug discoveryarrakistx.com

Arrakis Therapeutics is a private biopharmaceutical company developing orally bioavailable small molecules that directly bind disease-causing RNA, using a proprietary rSM drug discovery platform. It serves enterprise pharmaceutical partners (Roche, Amgen) via licensing collaborations and advances a wholly-owned DM1 candidate toward IND filing in 2026.

What Arrakis Therapeutics does

Arrakis Therapeutics is a private biopharmaceutical company founded in 2015 and headquartered in Waltham, Massachusetts, that pioneers the discovery of RNA-targeted small molecule (rSM) medicines — a new therapeutic class designed to directly bind and modulate disease-causing RNA structures with orally bioavailable small molecules. The company has built a proprietary end-to-end discovery platform integrating RNA bioinformatics (TRYST), photoaffinity-based binding site mapping (PEARL-seq), open-source structure analysis tools (SHAPEware), curated chemical libraries, RNA-specific assays, and AI/ML-driven chemotype analysis. Its lead wholly-owned candidate is an oral rSM for myotonic dystrophy type 1 (DM1), with IND filing planned for 2026 supported by preclinical data demonstrating splicing correction and myotonia reversal in vivo with broad biodistribution to skeletal muscle and heart.

The company operates a hybrid business model in which it generates revenue through strategic partnerships and licensing agreements with major pharmaceutical companies — notably a $190M upfront, multi-billion-dollar-potential collaboration with Roche (April 2020) and a $75M upfront, several-billion-dollar-potential collaboration with Amgen for RNA degrader therapeutics (January 2022) — while independently advancing its own pipeline in DM1, oncology, and genetically validated disease targets. Arrakis's customers are enterprise pharmaceutical partners rather than end patients or prescribers; Arrakis leads discovery to a defined point, then partners assume preclinical and clinical development. The company has raised approximately $113M in equity (Series A 2017, Series B 2019) and has not yet commercialized any product.

The company is led by CEO Michael Gilman (former founding CEO of Padlock Therapeutics and Stromedix; executive roles at Biogen and ARIAD), with Founder and Chief Innovation Officer Jennifer Petter (ex-Avila, Celgene, Mersana) and Board Chair Katrine Bosley (former CEO of Editas Medicine and Avila Therapeutics). Its Scientific Advisory Board is chaired by Melissa J. Moore, PhD, Chief Scientific Officer of Moderna's mRNA research platform and a National Academy of Sciences member. Headcount is 51-100, consistent with a mid-stage platform biotech scaling toward clinical development.

Arrakis Therapeutics firmographics

Firmographics
Name
Arrakis Therapeutics
Legal name
Arrakis Therapeutics
Website
https://arrakistx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Arrakis Therapeutics is a private biopharmaceutical company developing orally bioavailable small molecules that directly bind disease-causing RNA, using a proprietary rSM drug discovery platform. It serves enterprise pharmaceutical partners (Roche, Amgen) via licensing collaborations and advances a wholly-owned DM1 candidate toward IND filing in 2026.
Ownership category
akta.pro rank

Arrakis Therapeutics industry classification

Industry
Product category
RNA-targeted small molecule drug discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • RNA-targeted drug discovery
  • Small molecule therapeutics
  • Biopharmaceutical platform
  • Neuromuscular disease drugs
  • RNA bioinformatics

Where Arrakis Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Arrakis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership and Collaboration Revenue: Arrakis generates revenue through strategic partnerships with pharmaceutical companies. The company receives upfront payments, preclinical, clinical, and commercial milestone payments, and royalties on products developed through partnerships. Notable deals include Roche ($190M upfront, multi-billion dollar potential) and Amgen ($75M upfront, potential royalties up to low double digits per program)
  2. Series Financing: Pre-revenue biotech company funded through venture capital. Raised $38M Series A (2017) and $75M Series B (2019) from life sciences investors to advance platform development and pipeline programs

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Arrakis Therapeutics product offering

Product offering

Core offering

Arrakis Therapeutics develops RNA-targeted small molecule (rSM) drug candidates through a proprietary end-to-end discovery platform that integrates RNA bioinformatics, chemical biology, RNA-specific assays, and RNA-directed medicinal chemistry. Its lead internal asset is an orally bioavailable rSM drug candidate for myotonic dystrophy type 1 (DM1), with additional programs in oncology and genetically validated targets, and it monetizes the platform through major pharmaceutical collaborations with Roche and Amgen.

Product overview

Arrakis Therapeutics is a biopharmaceutical company pioneering RNA-targeted small molecule (rSM) medicines — a new class of genetic medicines that directly target RNA with small molecules for oral delivery. The company's offering centers on its proprietary rSM Platform, which integrates bioinformatics tools (TRYST), chemical biology techniques (PEARL-seq), and RNA-guided medicinal chemistry to systematically discover and design RNA-targeted small molecules. The rSM Toolkit provides industrial-scale discovery capabilities including SHAPEware (open-source bioinformatics software) for RNA structure analysis. The company's lead product is an oral rSM drug candidate for Myotonic Dystrophy Type 1 (DM1), with additional programs in oncology and genetically validated targets. The platform enables targeting of previously 'undruggable' disease drivers by binding directly to pathogenic RNA sequences.

Differentiator

Problem solved

Functional benefit

Products and services

  • DM1 Drug Candidate (oral RNA-targeted small molecule for myotonic dystrophy type 1) Lead first-in-class, orally administered RNA-targeted small molecule in development for myotonic dystrophy type 1 (DM1). The candidate selectively binds the pathogenic CUG repeat RNA, disrupts toxic nuclear aggregates, releases sequestered MBNL1 splicing factor, and corrects splicing defects that drive myotonia. Indication: patients with myotonic dystrophy type 1 (DM1), a genetic neuromuscular disease affecting skeletal muscle, heart, central nervous system, and gastrointestinal tract.
  • rSM Drug Discovery Platform Proprietary end-to-end drug discovery platform integrating RNA bioinformatics, structural tools, curated RNA-focused chemical libraries, RNA-specific assays, and RNA-directed medicinal chemistry to systematically discover and design RNA-targeted small molecules. Sold/offered to large pharmaceutical partners through strategic collaboration and licensing agreements; also used for internal pipeline development.
  • SHAPEware open-source bioinformatics software Standalone open-source bioinformatics software tool for analyzing SHAPE-based experimental data to explore and predict RNA secondary structure and potential ligand binding sites. Made freely available to academic and industry RNA researchers.

Quantifiable outcome

  • Oral administration achieved broad biodistribution including to skeletal muscle and heart in preclinical studies
  • +3 more outcomes

Companies that use Arrakis Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Arrakis Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Arrakis Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • AmgenflagshipStrategic or Co-development Partner · 11 January 2022Multi-target collaboration focused on discovery and development of RNA degrader therapeutics creating targeted RNA degraders that selectively destroy RNAs encoding disease-causing proteins by inducing their proximity to nucleases. Arrakis receives $75M upfront for five initial programs with option to nominate additional programs. Eligible for preclinical, clinical, regulatory and sales milestones, and royalties up to low double digits per program. Potential for several billion dollars if all milestones met and program options exercised.
  • RocheflagshipStrategic or Co-development Partner · 8 April 2020Strategic collaboration and license agreement for discovery of RNA-targeted small molecule drugs against broad set of targets across Roche's R&D areas. Arrakis leads discovery and research activities to a defined point, then Roche pursues preclinical and clinical development. Arrakis received $190M upfront payment with potential for multi-billion dollar future payments including preclinical, clinical, commercial and sales milestones and royalties.
  • Katrine Bosley (Board Member)coreStrategic or Co-development Partner · 21 November 2019Appointed as Chairman of the Board of Directors. Katrine Bosley is a proven biotech entrepreneur with nearly 30 years experience, former CEO of Editas Medicine and Avila Therapeutics. Brings expertise growing biotech platform companies.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Arrakis Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Ionis Pharmaceuticals: Ionis is the established leader in antisense oligonucleotide (ASO) therapeutics with multiple approved drugs (Spinraza, Tegsedi, Waylivra, Wainua) and a broad pipeline across neurological, cardiovascular, and rare diseases. As the incumbent in RNA-targeted therapeutics, Ionis is broadly comparable to Arrakis in disease focus (neurology, rare diseases) and represents the alternative modality (ASOs vs. rSMs) for many of the same targets Arrakis is pursuing.
  • Alnylam Pharmaceuticals: Alnylam is the commercial leader in RNA interference (siRNA) therapeutics with multiple approved drugs (Onpattro, Givlaari, Oxlumo, Amvuttra) and a deep pipeline in rare genetic and cardiometabolic diseases. Broadly comparable to Arrakis in therapeutic focus on genetic and rare diseases and as the dominant incumbent in the RNA-targeting therapeutic space, though using a fundamentally different modality (siRNA vs. rSMs).

Emerging players

  • Wave Life Sciences: Wave Life Sciences is developing stereopure oligonucleotide therapeutics (PRISM platform) for genetic diseases including DM1, Huntington's disease, and ALS. Comparable to Arrakis in target overlap (DM1, repeat expansion disorders, CNS diseases) and as a competitor pursuing RNA-modulating therapies for the same indications, though via oligonucleotide chemistry rather than small molecules.
  • PepGen: PepGen is developing conjugated peptide-enhanced oligonucleotide therapeutics for DM1 and Duchenne muscular dystrophy, with a proprietary delivery platform (Enhanced Delivery Oligonucleotide). Directly comparable to Arrakis in DM1 focus and in pursuing RNA-targeting therapeutics for neuromuscular diseases, though using a distinct modality (conjugated oligonucleotides vs. rSMs).

Direct peers

  • Skyhawk Therapeutics: Skyhawk Therapeutics develops small molecules that modify RNA splicing using a proprietary platform (SkySTAR) — directly comparable to Arrakis's rSM platform in both modality (RNA-targeting small molecules) and therapeutic focus on neurological and rare diseases. Skyhawk has secured major partnerships with Biogen, Vertex, and Merck, mirroring Arrakis's partnership-driven business model.
  • Expansion Therapeutics: Expansion Therapeutics is a repeat-expansion-focused company developing small molecules for diseases caused by trinucleotide and other repeat expansions, including myotonic dystrophy type 1 (DM1) — directly competing with Arrakis's lead DM1 program. Expansion's lead program EX-5050 for DM1 makes it the most direct indication-level competitor to Arrakis.
  • Remix Therapeutics: Remix Therapeutics is developing small molecule therapeutics that modulate RNA processing, with a platform (REMaster) targeting RNA processing machinery to address disease-driving transcripts. Directly comparable to Arrakis in approach (RNA-targeted small molecules) and focus on previously undruggable disease targets across oncology and neurological disease.
  • Ribometrix: Ribometrix is a privately held biotech developing small molecule drugs that target RNA structures, with a proprietary platform combining structural biology, chemistry, and computational methods to identify and optimize RNA-binding small molecules. Directly comparable to Arrakis in technology approach (RNA-targeted small molecules) and platform-driven discovery model.
  • Dyne Therapeutics: Dyne Therapeutics is developing oligonucleotide-based therapies for muscle diseases including DM1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy, with a proprietary platform for muscle-targeted delivery. Directly comparable to Arrakis in DM1 focus and in targeting muscle diseases via RNA-modulating approaches, though using a different modality (antisense oligonucleotides).
  • PTC Therapeutics: PTC Therapeutics is advancing RGLS8429, an oligonucleotide-based therapy for DM1, into clinical development — making it a direct indication-level competitor to Arrakis's lead DM1 program. As an established commercial-stage rare disease biotech, PTC represents the most credible near-term competitive threat in the DM1 indication Arrakis is targeting with its lead rSM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Arrakis Therapeutics social profiles

Digital presence

Arrakis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arrakis Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

Arrakis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arrakis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arrakis Therapeutics

What does Arrakis Therapeutics do?

Arrakis Therapeutics develops RNA-targeted small molecule (rSM) drug candidates through a proprietary end-to-end discovery platform that integrates RNA bioinformatics, chemical biology, RNA-specific assays, and RNA-directed medicinal chemistry. Its lead internal asset is an orally bioavailable rSM drug candidate for myotonic dystrophy type 1 (DM1), with additional programs in oncology and genetically validated targets, and it monetizes the platform through major pharmaceutical collaborations with Roche and Amgen.

Is Arrakis Therapeutics a public or private company?

Arrakis Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Arrakis Therapeutics founded?

Arrakis Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Arrakis Therapeutics based?

Arrakis Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Arrakis Therapeutics make money?

Two revenue lines are on record. Partnership and Collaboration Revenue is the primary driver. The others are series Financing.

Who are Arrakis Therapeutics's main competitors?

Broad incumbents on record are Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Emerging players are Wave Life Sciences and PepGen. Direct peers are Skyhawk Therapeutics, Expansion Therapeutics, Remix Therapeutics, Ribometrix, Dyne Therapeutics and PTC Therapeutics.

Does Arrakis Therapeutics have an API?

No public API is recorded for Arrakis Therapeutics.

What industry is Arrakis Therapeutics in?

Arrakis Therapeutics's product category is RNA-targeted small molecule drug discovery. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizArrakis Therapeutics Names Mark DeLong CEO Ahead of Clinical-Stage TransitionArrakis Therapeutics appointed biotech executive Mark DeLong as CEO, effective June 29, 2026, during a transition phase as the company moves towards becoming a clinical-stage biopharmaceutical company. The company is advancing its lead RNA-targeted small molecule therapy for myotonic dystrophy type 1 (DM1), aiming to address the disease's genetic root.GlobeNewswireArrakis Therapeutics Announces CEO Transition with Mark DeLong Appointed as New CEOArrakis Therapeutics appointed Mark DeLong as CEO effective June 29, 2026, following Michael Gilman's retirement. DeLong will lead the company as it advances its oral RNA-targeted small molecule for myotonic dystrophy type 1. Michael Gilman will become Chairman, and Katrine Bosley steps down from the Board.GlobeNewswireArrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)Arrakis Therapeutics presented preclinical data on its oral RNA-targeted small molecule for myotonic dystrophy type 1, showing splicing correction and myotonia reversal in an animal model. The drug also showed broad biodistribution to skeletal muscle and heart, supporting once-daily dosing. The company plans to file an IND with the U.S. FDA in 2026.GlobeNewswireArrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)Arrakis Therapeutics presented preclinical data at the 8th Annual RNA-Targeted Drug Discovery and Development Summit demonstrating progress of its RNA-targeted small molecule (rSM) drug program for myotonic dystrophy type 1 (DM1). The in vivo studies showed that oral administration of the lead rSM series achieved broad biodistribution to skeletal muscle and heart, corrected mRNA splicing defects, and reversed myotonia in animal models, with pharmacokinetics supporting once-daily dosing. The company plans to file an Investigational New Drug (IND) application with the U.S. FDA in 2026 for the oral DM1 treatment candidate.MassbioMassLive: Biotech slump: US risks losing its industry crown to China, Mass. leaders sayIndustry veterans express concern that the U.S. biotech sector may lose its competitive edge to China due to declining employment in manufacturing and research jobs. A report from MassBio highlights these issues, including high interest rates and government policies affecting research funding and drug pricing. The CEO of Arrakis Therapeutics emphasizes the existential threats posed to the scientific infrastructure and healthcare delivery in the U.S.Endpoints NewsPeer Review channel feed – Endpoints NewsThe article provides a summary of recent executive and leadership changes in the biotech and pharmaceutical industries. Several companies including iTeos, Arrakis, Moderna, Novo, Amgen, AC Immune, Lilly, and others announced retirements, new hires, or leadership shifts.Business Wire BlogArrakis Therapeutics Announces Oral Presentation Describing RNA-targeted Small Molecule to Treat Myotonic Dystrophy at MDA Conference 2025Arrakis Therapeutics announced it will present preclinical data for its RNA-targeted small molecule drug program targeting myotonic dystrophy type 1 (DM1) at the Muscular Dystrophy Association 2025 Conference. The presentation, scheduled for March 19 in Dallas, Texas, details how the compound binds to CUG repeats to disrupt pathogenic aggregates and improve disease pathology in animal models.openPR.comBest Statistical RNA Targeted Therapeutics Market Growth Set to Surge Significantly during 2025 to 2032 | Abivax, AC Immune, Arrakis Therapeutics, eFFECTOR TherapeuticsThe RNA targeted therapeutics market is projected to grow from USD 1.34 billion in 2024 to USD 11.2 billion by 2031, a CAGR of 35.2%. Key players include Abivax, AC Immune, Arrakis Therapeutics, and eFFECTOR Therapeutics, with segmentation by target molecule and approach.FierceBiotechRNA-targeting molecule from Arrakis allows muscles to relax in mice with myotonic dystrophyArrakis Therapeutics has tested an RNA-targeting small molecule in a mouse model of myotonic dystrophy type 1 (DM1), successfully reversing the prolonged muscle contraction characteristic of the disease. The results were presented at a conference in San Francisco on Dec. 4, and Arrakis’ molecule binds to errant RNA sequences, restoring normal RNA splicing in muscle cells. Arrakis aims to develop more RNA-targeted drug candidates from its platform in the future.